NCT00454584View on ClinicalTrials.gov

An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

903

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2009

Conditions
Psoriasis
Interventions
DRUG

CNTO 1275 45 mg

Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous

DRUG

CNTO 1275 90 mg

Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous

DRUG

Etanercept 50 mg

Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY